- Home
- DTIL vs LUCD Comparison
DTIL vs LUCD Comparison
Compare DTIL & LUCD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DTIL | LUCD |
|---|---|---|
| Founded | 2006 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 197.9M | 192.9M |
| IPO Year | 2019 | 2021 |
Fundamental Metrics
Financial Performance| Metric | DTIL | LUCD |
|---|---|---|
| Price | $6.36 | $0.84 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | ★ $45.00 | $4.13 |
| AVG Volume (30 Days) | 231.4K | ★ 980.7K |
| Earning Date | 05-14-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 16.67 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,070,000,000.00 | $4,346,000.00 |
| Revenue This Year | N/A | $115.58 |
| Revenue Next Year | N/A | $130.54 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 79.00 |
| 52 Week Low | $3.53 | $0.75 |
| 52 Week High | $9.62 | $1.63 |
Technical Indicators
Market Signals| Indicator | DTIL | LUCD |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 49.46 |
| Support Level | N/A | $0.88 |
| Resistance Level | N/A | $1.09 |
| Average True Range (ATR) | 0.00 | 0.06 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 0.00 | 56.59 |
Price Performance
Historical ComparisonAbout DTIL Precision BioSciences Inc.
Precision BioSciences Inc clinical stage gene editing company utilizing its proprietary ARCUS platform to concurrently develop two clinical-stage in vivo gene editing therapies. The ARCUS platform is used to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion (inserting DNA into gene to cause expression/add function), elimination (removing a genome, e.g. viral DNA), and excision (removing a large portion of a defective gene by delivering two ARCUS nucleases in a single adeno-associated virus ("AAV")).
About LUCD Lucid Diagnostics Inc.
Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically lethal esophageal adenocarcinoma. Its products include EsoCheck and EsoGuard.